![Gary Abromovitz](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Gary Abromovitz
Keine laufenden Positionen mehr
Karriereverlauf von Gary Abromovitz
Ehemalige bekannte Positionen von Gary Abromovitz
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
HELEN OF TROY LIMITED | Direktor/Vorstandsmitglied | 01.01.1990 | 24.08.2022 |
Independent Dir/Board Member | 01.01.1990 | 24.08.2022 | |
Venturis Therapeutics, Inc.
![]() Venturis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Venturis Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX. | Direktor/Vorstandsmitglied | 01.02.2005 | 10.08.2012 |
Independent Dir/Board Member | 01.02.2005 | 10.08.2012 |
Statistik
International
Bermuda | 2 |
Vereinigte Staaten | 2 |
Operativ
Director/Board Member | 2 |
Independent Dir/Board Member | 2 |
Sektoral
Consumer Durables | 2 |
Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
HELEN OF TROY LIMITED | Consumer Durables |
Private Unternehmen | 1 |
---|---|
Venturis Therapeutics, Inc.
![]() Venturis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Venturis Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX. | Commercial Services |
- Börse
- Insiders
- Gary Abromovitz
- Erfahrung